490 related articles for article (PubMed ID: 21896671)
1. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
2. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
Gómez R; Lima I; Simón C; Pellicer A
Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
Gómez R; Simón C; Remohí J; Pellicer A
Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
[TBL] [Abstract][Full Text] [Related]
4. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
[TBL] [Abstract][Full Text] [Related]
6. Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor.
van de Lagemaat R; Timmers CM; Kelder J; van Koppen C; Mosselman S; Hanssen RG
Hum Reprod; 2009 Mar; 24(3):640-8. PubMed ID: 19088107
[TBL] [Abstract][Full Text] [Related]
7. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
[TBL] [Abstract][Full Text] [Related]
8. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
Rizk B; Aboulghar M; Smitz J; Ron-El R
Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
[TBL] [Abstract][Full Text] [Related]
9. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
[TBL] [Abstract][Full Text] [Related]
10. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Steroidogenic and Ovulation-Inducing Effects of Orthosteric and Allosteric Agonists of Luteinizing Hormone/Chorionic Gonadotropin Receptor in Immature Female Rats.
Derkach KV; Lebedev IA; Morina IY; Bakhtyukov AA; Pechalnova AS; Sorokoumov VN; Kuznetsova VS; Romanova IV; Shpakov AO
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068943
[TBL] [Abstract][Full Text] [Related]
12. Physiology and pathology of ovarian hyperstimulation syndrome.
Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
[TBL] [Abstract][Full Text] [Related]
13. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic induction of ovulation: towards the replacement of hCG with LH].
Emperaire JC
Contracept Fertil Sex; 1994; 22(7-8):459-67. PubMed ID: 7920947
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
[TBL] [Abstract][Full Text] [Related]
17. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
[TBL] [Abstract][Full Text] [Related]
18. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.
Neulen J; Yan Z; Raczek S; Weindel K; Keck C; Weich HA; Marmé D; Breckwoldt M
J Clin Endocrinol Metab; 1995 Jun; 80(6):1967-71. PubMed ID: 7775647
[TBL] [Abstract][Full Text] [Related]
19. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
[TBL] [Abstract][Full Text] [Related]
20. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.
Bishop CV; Lee DM; Slayden OD; Li X
J Ovarian Res; 2017 Jul; 10(1):41. PubMed ID: 28683759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
